Literature DB >> 34865692

Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?

James M Foran1.   

Abstract

Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights into factors that influence treatment choices among older patients with AML and what we would need to know for venetoclax-based therapy to replace standard intensive 7 + 3 induction therapy.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  7+3; AML; Acute myeloid leukemia; Azacytidine; CR; Complete remission; Intensive chemotherapy; OS; Overall survival; Venetoclax

Mesh：

Substances：

Year:  2021        PMID： 34865692     DOI： 10.1016/j.beha.2021.101335

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  1 in total

1.  A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

Authors:  Christoph Röllig; Pierre-Yves Dumas; Pau Montesinos; Christian Récher; Emilie Bérard; Sarah Bertoli; Arnaud Pigneux; Suzanne Tavitian; Michael Kramer; Hubert Serve; Martin Bornhäuser; Uwe Platzbecker; Carsten Müller-Tidow; Claudia D Baldus; David Martínez-Cuadrón; Josefina Serrano; Pilar Martínez-Sánchez; Eduardo Rodríguez Arbolí; Cristina Gil; Juan Bergua; Teresa Bernal; Adolfo de la Fuente Burguera; Eric Delabesse; Audrey Bidet
Journal:  Blood Cancer J       Date:  2022-07-11       Impact factor: 9.812
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.